Dianthus Therapeutics, Inc. (DNTH)
88.16
-3.65
(-3.98%)
USD |
NASDAQ |
Nov 16, 14:20
Dianthus Therapeutics Enterprise Value : 4.332B for Nov. 13, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2026 | 4.332B |
| November 12, 2026 | 4.370B |
| November 11, 2026 | 4.191B |
| November 10, 2026 | 4.163B |
| November 09, 2026 | 4.230B |
| November 06, 2026 | 4.007B |
| November 05, 2026 | 3.836B |
| November 04, 2026 | 3.994B |
| November 03, 2026 | 3.819B |
| November 02, 2026 | 3.794B |
| October 30, 2026 | 3.801B |
| October 29, 2026 | 3.819B |
| October 28, 2026 | 3.797B |
| October 27, 2026 | 3.640B |
| October 26, 2026 | 3.629B |
| October 23, 2026 | 3.486B |
| October 22, 2026 | 3.584B |
| October 21, 2026 | 3.560B |
| October 20, 2026 | 3.597B |
| October 19, 2026 | 3.360B |
| October 16, 2026 | 3.222B |
| October 15, 2026 | 3.359B |
| October 14, 2026 | 3.372B |
| October 13, 2026 | 3.531B |
| October 12, 2026 | 3.755B |
| Date | Value |
|---|---|
| October 09, 2026 | 3.800B |
| October 08, 2026 | 3.804B |
| October 07, 2026 | 3.942B |
| October 06, 2026 | 3.971B |
| October 05, 2026 | 4.120B |
| October 02, 2026 | 4.129B |
| October 01, 2026 | 4.135B |
| September 30, 2026 | 4.120B |
| September 29, 2026 | 3.891B |
| September 28, 2026 | 3.927B |
| September 25, 2026 | 3.967B |
| September 24, 2026 | 4.085B |
| September 23, 2026 | 4.235B |
| September 22, 2026 | 4.504B |
| September 21, 2026 | 4.401B |
| September 18, 2026 | 4.419B |
| September 17, 2026 | 4.656B |
| September 16, 2026 | 4.731B |
| September 15, 2026 | 4.856B |
| September 14, 2026 | 5.016B |
| September 11, 2026 | 4.934B |
| September 10, 2026 | 4.774B |
| September 09, 2026 | 4.980B |
| September 08, 2026 | 5.095B |
| September 04, 2026 | 5.038B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Xencor, Inc. | 2.528B |
| ACADIA Pharmaceuticals, Inc. | 2.335B |
| Alnylam Pharmaceuticals, Inc. | 21.50B |
| Anika Therapeutics, Inc. | 160.67M |
| Savara, Inc. | 854.40M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -46.64M |
| Revenue (Quarterly) | 1.21M |
| Total Expenses (Quarterly) | 47.85M |
| EPS Diluted (Quarterly) | -0.8134 |
| Gross Profit Margin (Quarterly) | 90.99% |
| Profit Margin (Quarterly) | -3.85K% |
| Earnings Yield | -4.53% |
| Normalized Earnings Yield | -4.529 |